Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,cash,totalCurrentLiabilities,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,totalCashflowsFromInvestingActivities,otherCashflowsFromInvestingActivities,changeToInventory,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingPE,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GCAN,-377496,478638016,,,-114653,,-114653,51000,-1250,-86232,-86232,33982,-12747,,,,0,0,86232,1250,-28421,,-114653,-114653,19167,2608093,721556,-358329,260905,372639,478639,-3445061,316722,721556,353472,36750,4493,-2250.0,250000.0,250000.0,41670.0,203769.0,-46231.0,1250.0,15674.0,,,,,-368084,en-US,US,EQUITY,False,Delayed Quote,POST,USD,PNK,GREATER CANNABIS CO INC,us_market,4,Other OTC,"The Greater Cannabis Company, Inc.",USD,2705581,1650913,0.0034,1.9428571,0.00175 - 0.0241,-0.01895,-0.7863071,0.00175,0.0241,5.1499996,0.001,0,-0.001,0.0054688887,-0.00031888857,-0.058309574,0.00868176,-0.00353176,-0.4068023,2464985,-5.1499996,15,America/New_York,EDT,-14400000,False,False,-0.9615368,0.0049 - 0.0054,0.0052,0.0,0.0,0,0,finmb_576310974,0.00515,1630526335,-4.9999915e-05,0.005295,0.0054,0.0049,1387491,1.01,,,0.0241,0.0018,0.0055,0.0087,2.71M,1.65M,478.64M,,472.36M,100.53%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",303.36%,-609.01%,-50.79%,,48.04k,0.00,,-4.63k,-287.59k,145.75k,0.0010,,316.72k,0,272.45k,,0.49,-0.00,-204.84k,-1.4M,Value,21208,Healthcare,2,"The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company was founded in 2014 and is based in Baltimore, Maryland.",Baltimore,443 738 4051,MD,1609372800,United States,http://www.gcanrx.com,86400,15 Walker Avenue,Drug Manufacturers—Specialty & Generic,Suite 101
t-1,GCAN,-309617,478638016,,,-382790,,-382790,51000,-1250,-53532,-53532,1282,-175490,,,,0,0,53532,1250,-329258,,-382790,-382790,20417,2576365,459908,-289200,17441,180120,464843,-3330408,112953,459908,159703,36750,6743,-220.0,250000.0,250000.0,53613.0,-65679.0,-28929.0,1250.0,153768.0,-36750.0,-36750.0,,,-300205,en-US,US,EQUITY,False,Delayed Quote,POST,USD,PNK,GREATER CANNABIS CO INC,us_market,4,Other OTC,"The Greater Cannabis Company, Inc.",USD,2705581,1650913,0.0034,1.9428571,0.00175 - 0.0241,-0.01895,-0.7863071,0.00175,0.0241,5.1499996,0.001,0,-0.001,0.0054688887,-0.00031888857,-0.058309574,0.00868176,-0.00353176,-0.4068023,2464985,-5.1499996,15,America/New_York,EDT,-14400000,False,False,-0.9615368,0.0049 - 0.0054,0.0052,0.0,0.0,0,0,finmb_576310974,0.00515,1630526335,-4.9999915e-05,0.005295,0.0054,0.0049,1387491,1.01,,,0.0241,0.0018,0.0055,0.0087,2.71M,1.65M,478.64M,,472.36M,100.53%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",303.36%,-609.01%,-50.79%,,48.04k,0.00,,-4.63k,-287.59k,145.75k,0.0010,,316.72k,0,272.45k,,0.49,-0.00,-204.84k,-1.4M,Value,21208,Healthcare,2,"The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company was founded in 2014 and is based in Baltimore, Maryland.",Baltimore,443 738 4051,MD,1609372800,United States,http://www.gcanrx.com,86400,15 Walker Avenue,Drug Manufacturers—Specialty & Generic,Suite 101
t-2,GCAN,-732401,478638016,,,-459260,,-459260,51000,-1250,-70925,-70925,18675,-184531,,,,0,0,70925,1250,-388335,,-459260,-459260,21667,2033257,925196,-710734,325935,223874,203627,-2947618,178632,925196,202207,23575,6963,-1213.0,250000.0,250000.0,27253.0,-49886.0,-49886.0,1250.0,203804.0,-36750.0,-36750.0,,,-722989,en-US,US,EQUITY,False,Delayed Quote,POST,USD,PNK,GREATER CANNABIS CO INC,us_market,4,Other OTC,"The Greater Cannabis Company, Inc.",USD,2705581,1650913,0.0034,1.9428571,0.00175 - 0.0241,-0.01895,-0.7863071,0.00175,0.0241,5.1499996,0.001,0,-0.001,0.0054688887,-0.00031888857,-0.058309574,0.00868176,-0.00353176,-0.4068023,2464985,-5.1499996,15,America/New_York,EDT,-14400000,False,False,-0.9615368,0.0049 - 0.0054,0.0052,0.0,0.0,0,0,finmb_576310974,0.00515,1630526335,-4.9999915e-05,0.005295,0.0054,0.0049,1387491,1.01,,,0.0241,0.0018,0.0055,0.0087,2.71M,1.65M,478.64M,,472.36M,100.53%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",303.36%,-609.01%,-50.79%,,48.04k,0.00,,-4.63k,-287.59k,145.75k,0.0010,,316.72k,0,272.45k,,0.49,-0.00,-204.84k,-1.4M,Value,21208,Healthcare,2,"The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company was founded in 2014 and is based in Baltimore, Maryland.",Baltimore,443 738 4051,MD,1609372800,United States,http://www.gcanrx.com,86400,15 Walker Avenue,Drug Manufacturers—Specialty & Generic,Suite 101
t-3,GCAN,-1071458,478638016,,,1102449,,1102449,51000,-1296,-81903,-81903,29607,-402766,,,,0,48044,129947,49340,1184352,,1102449,1102449,22917,1351467,1314139,-1048541,539686,275010,88350,-2488358,228518,1314139,252093,23575,8176,3409.0,83001.0,13001.0,-22587.0,-66796.0,-79797.0,1250.0,-1587118.0,-36750.0,-36750.0,28000.0,-70000.0,-1062046,en-US,US,EQUITY,False,Delayed Quote,POST,USD,PNK,GREATER CANNABIS CO INC,us_market,4,Other OTC,"The Greater Cannabis Company, Inc.",USD,2705581,1650913,0.0034,1.9428571,0.00175 - 0.0241,-0.01895,-0.7863071,0.00175,0.0241,5.1499996,0.001,0,-0.001,0.0054688887,-0.00031888857,-0.058309574,0.00868176,-0.00353176,-0.4068023,2464985,-5.1499996,15,America/New_York,EDT,-14400000,False,False,-0.9615368,0.0049 - 0.0054,0.0052,0.0,0.0,0,0,finmb_576310974,0.00515,1630526335,-4.9999915e-05,0.005295,0.0054,0.0049,1387491,1.01,,,0.0241,0.0018,0.0055,0.0087,2.71M,1.65M,478.64M,,472.36M,100.53%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",303.36%,-609.01%,-50.79%,,48.04k,0.00,,-4.63k,-287.59k,145.75k,0.0010,,316.72k,0,272.45k,,0.49,-0.00,-204.84k,-1.4M,Value,21208,Healthcare,2,"The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company was founded in 2014 and is based in Baltimore, Maryland.",Baltimore,443 738 4051,MD,1609372800,United States,http://www.gcanrx.com,86400,15 Walker Avenue,Drug Manufacturers—Specialty & Generic,Suite 101
